Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01453023 · ClinicalTrials.gov registry record · Phase 2
Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT01453023 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 26 participants.
The verdict
NCT01453023, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study will investigate the safety and tolerability, pharmacokinetics, and pharmacodynamics of fluticasone furoate/vilanterol (FF/VI) 100/25mcg administered using the novel dry powder inhaler in children aged 5 to 11 years with persistent asthma.
Interventions
- DRUG Fluticasone Furoate/Vilanterol
- DRUG Fluticasone Furoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01453023
The ClinicalTrials.gov registry entry for NCT01453023 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluticasone Furoate/Vilanterol is the first listed.
NCT01453023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01453023 about?
NCT01453023 is a clinical study titled "Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study". This study will investigate the safety and tolerability, pharmacokinetics, and pharmacodynamics of fluticasone furoate/vilanterol (FF/VI) 100/25mcg administered using the novel dry powder inhaler in children aged 5 to 11 years with persistent asthma.
What is the current status of trial NCT01453023?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2011-10. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01453023?
The interventions under investigation include: Fluticasone Furoate/Vilanterol (DRUG), Fluticasone Furoate (DRUG).
Who is sponsoring clinical trial NCT01453023?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.